CellaVision
226.5 SEK -0.44%1,503 investors are following this company
CellaVision is active in medical technology. The company's operations develop and market image analysis systems for diagnosing blood and other body fluids. The products are intended to replace traditional microscope analysis. Operations are conducted on a global level, primarily in the Nordic countries, Europe and North America, where customers consist of research institutes. The head office is located in Lund.
Revenue
677.29M
EBIT %
24.66 %
P/E
41.48
Dividend yield-%
0.99 %
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
CEVI
Daily low / high price
223.5 / 229.5
SEK
Market cap
5.4B SEK
Turnover
1.43M SEK
Volume
6.3K
Latest videos
Financial calendar
Annual dividend
2024-05-06
Interim report
2024-07-19
Interim report
2024-10-24
Annual report
2025-02-06
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
William Demant Invest | 19.9 % | 19.9 % |
Grenlunden CEVI AB | 10.0 % | 10.0 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Bulletin from the Annual General Meeting of CellaVision AB (publ)
Redeye: Cellavision - Trend is still their friend
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools